Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.4 - $0.56 $9,710 - $13,595
-24,277 Reduced 21.03%
91,181 $36,000
Q1 2024

May 14, 2024

BUY
$0.53 - $1.89 $3,464 - $12,353
6,536 Added 6.0%
115,458 $61,000
Q4 2023

Feb 13, 2024

BUY
$1.22 - $5.24 $82,877 - $355,963
67,932 Added 165.73%
108,922 $137,000
Q3 2023

Nov 13, 2023

SELL
$2.75 - $5.17 $6,066 - $11,405
-2,206 Reduced 5.11%
40,990 $139,000
Q2 2023

Aug 11, 2023

BUY
$4.09 - $8.29 $94,638 - $191,822
23,139 Added 115.37%
43,196 $186,000
Q1 2023

May 15, 2023

BUY
$4.89 - $10.53 $36,362 - $78,301
7,436 Added 58.92%
20,057 $162,000
Q4 2022

Feb 13, 2023

BUY
$3.86 - $42.0 $48,717 - $530,082
12,621 New
12,621 $98,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $92M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.